SYNGENE Q4 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,018 Cr
verified against source
Revenue YoY
11%
reported change
EBITDA
₹344 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene closed Q4 FY25 with revenue from operations crossing INR 1,080 crore for the first time, an 11% YoY increase, driven by strong performance in research services and large molecule CDMO partially offset by small molecule weakness. Operating EBITDA stood at INR 344 crore (34% margin) with PAT at INR 183 crore (down 3% YoY). The acquisition of a Baltimore biologics facility adds strategic U.S. footprint and brings total single-use bioreactor capacity to ~50,000 liters. Full-year FY25 revenue grew 4% with 28.6% EBITDA margin. For FY26, management guides underlying revenue growth in early teens but reported growth in mid-single digits due to biologics inventory normalization from the Zoetis animal health contract. EBITDA margins are expected to moderate to mid-20s as Unit 3 and Baltimore facilities ramp up. PAT will decline due to higher depreciation and effective tax rate (26%). The key risk is the uncertain biotech funding recovery and facility ramp-up costs weighing on near-term profitability.
Colored figures show movement against the previous available record.
Guidance to track
- Expected broad-based growth across research services, small and large molecule CDMO businesses, underpinned by pipeline visibility and pilot program conversions.
- Adjusted for client inventory rebalancing in biologics commercial manufacturing (Zoetis animal health product normalizing to ~$50M annual run rate from elevated pre-launch/launch volumes).
- Margins expected to moderate from 28.6% in FY25 due to operating costs from new Unit 3 and Baltimore facilities coming online, with gestation and ramp-up period.
- PAT expected to decline due to increased depreciation from new facilities and higher effective tax rate rising to 26% as SEZ units exit tax holidays.
Risks flagged
- Small molecule segment declined 24% YoY due to client clinical program setbacks and reduced annual commercial manufacturing volumes. Though pipeline fill is improving, execution remains uncertain.
- The Zoetis animal health commercial contract delivered volumes above the $50M annual run rate during pre-launch/launch phase (2.5 years of 10-year contract). These volumes are expected to moderate to annualized contract average in FY2026, creating a reported revenue headwind.
- Unit 3 (India) awaiting regulatory licenses with capitalization expected in Q1 FY26; Baltimore facility integration ongoing with commercial operations targeted for H2 FY26. Operating costs will weigh on margins through ramp-up period.
- Analyst questioned whether the TAM for discovery services has reduced despite Syngene gaining market share. Management attributed pipeline strength to China+1 rebalancing from pharma companies rather than biotech funding recovery.
Key quotes
- Within the global CRDMO market, large molecule biologics development and manufacturing is the fastest-growing segment. The acquisition that we've made plays into this market opportunity, and Syngene's total single-use bioreactor capacity for production of monoclonal antibodies has now increased to around 50,000 liters.
- We expect FY 2026 to be a transit year with uncertain short-term macro environment building in the recovery of biotech funding, big pharma restructuring, and tempering of urgency on the Biosecure Act.
- The way to think about this is the fact that these are manufacturing sites, and we've given a direction of when these sites will become operational. As and when these sites get operationalized and its capacity starts getting utilized, you will start seeing the drag come down.
Research modules